This company has been acquired
Chembio Diagnostics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-34.2%
Tasa de crecimiento de los beneficios
-19.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 8.9% |
| Tasa de crecimiento de los ingresos | 14.6% |
| Rentabilidad financiera | -130.9% |
| Margen neto | -47.0% |
| Última actualización de beneficios | 31 Dec 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Chembio gets $3.2M contract from CDC to develop rapid test for syphilis
Sep 06Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Aug 16Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?
Nov 30
Analysts' Revenue Estimates For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Are Surging Higher
Aug 08Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?
Jul 22Chembio Diagnostics EPS beats by $0.10, beats on revenue
May 06Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt Sensibly?
Apr 07Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders?
Jan 16Chembio stock gains after COVID-19 tests nab European Union nod
Jan 14Is Chembio Diagnostics (NASDAQ:CEMI) Weighed On By Its Debt Load?
Dec 12
Chembio slumps 13% on delay of U.S. nod for coronavirus antibody test
Dec 04Chembio nabs BARDA contract for rapid respiratory antigen panel test
Dec 02Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Chembio Diagnostics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 22 | 50 | -23 | 24 | 0 |
| 30 Sep 22 | 60 | -36 | 25 | 0 |
| 30 Jun 22 | 61 | -36 | 25 | -2 |
| 31 Mar 22 | 58 | -38 | 26 | 0 |
| 31 Dec 21 | 48 | -34 | 25 | 0 |
| 30 Sep 21 | 37 | -27 | 25 | 0 |
| 30 Jun 21 | 36 | -26 | 25 | 6 |
| 31 Mar 21 | 34 | -25 | 23 | 0 |
| 31 Dec 20 | 32 | -26 | 21 | 0 |
| 30 Sep 20 | 29 | -22 | 17 | 0 |
| 30 Jun 20 | 28 | -21 | 16 | 0 |
| 31 Mar 20 | 33 | -16 | 16 | 0 |
| 31 Dec 19 | 34 | -14 | 16 | 0 |
| 30 Sep 19 | 35 | -13 | 16 | 0 |
| 30 Jun 19 | 37 | -11 | 14 | 0 |
| 31 Mar 19 | 35 | -10 | 13 | 0 |
| 31 Dec 18 | 35 | -8 | 11 | 0 |
| 30 Sep 18 | 33 | -7 | 10 | 0 |
| 30 Jun 18 | 30 | -5 | 9 | 0 |
| 31 Mar 18 | 25 | -5 | 9 | 0 |
| 31 Dec 17 | 24 | -6 | 9 | 0 |
| 30 Sep 17 | 22 | -7 | 9 | -6 |
| 30 Jun 17 | 18 | -8 | 9 | -4 |
| 31 Mar 17 | 18 | -15 | 8 | -2 |
| 31 Dec 16 | 18 | -13 | 8 | 0 |
| 30 Sep 16 | 18 | -11 | 7 | 8 |
| 30 Jun 16 | 21 | -10 | 7 | 7 |
Ingresos de calidad: CEMI is currently unprofitable.
Margen de beneficios creciente: CEMI is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CEMI is unprofitable, and losses have increased over the past 5 years at a rate of 34.2% per year.
Acelerando crecimiento: Unable to compare CEMI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: CEMI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-5.5%).
Rentabilidad financiera
Alta ROE: CEMI has a negative Return on Equity (-130.86%), as it is currently unprofitable.